Gilead Sciences GILD AmBisome — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's ambisome — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's ambisome — total revenues?
- Gilead Sciences (GILD) reported ambisome — total revenues of $138M in Q1 2026.
- How has Gilead Sciences's ambisome — total revenues changed year-over-year?
- Gilead Sciences's ambisome — total revenues decreased by 0.7% year-over-year, from $139M to $138M.
- What is the long-term trend for Gilead Sciences's ambisome — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's ambisome — total revenues has grown at a -1.5% compound annual growth rate (CAGR), from $540M to $509M.
- What does ambisome — total revenues mean?
- The total revenue generated from sales of the AmBisome antifungal medication.
- How do you interpret ambisome — total revenues?
- An increase indicates strong market demand or successful clinical adoption of the therapy, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
- How does ambisome — total revenues compare across companies?
- Comparable to revenue streams from legacy or specialty branded pharmaceutical products at other biopharmaceutical companies, often evaluated based on market share and therapeutic relevance.